https://doi.org/10.55788/d6029be1
The presence of ANAs is a classification criterion for RA and other systemic autoimmune rheumatic diseases (SARD), making ANA immunofluorescence (IFA) patterns and titers a key part of diagnostics. Dr May Choi (University of Calgary, Canada) and colleagues developed 8 machine-learning models to aid laboratories in ANA pattern and titer interpretation to reduce the considerable variability within and between laboratories that occurs with manual interpretation [1]. One model specifically assessed the nuclear dense fine-speckled (DFS) ANA pattern (AC-2), a rare pattern that decreases the likelihood of SARD.
To compare the performance of the 8 machine-learning models in recognising 13 ANA patterns, the researchers fed their models 13,671 ANA images from patients enrolled in the Systemic Lupus International Collaborating Clinics Inception Cohort (SLICC, n=2,825 images), non-SLE subjects enrolled in the Ontario Health Study (OHS, n=10,639 images), and the International Consensus on ANA Patterns (ICAP, n=207 images). As the reference standard, a highly experienced laboratory technologist interpreted ANA patterns and titers for each image.
The ANA Reader© model had the best performance of all 8 machine-learning techniques. It had the highest area under the curve (AUC) score of 83.4%, albeit with modest performance in other metrics: weighted accuracy was 68.4%, precision 67.1%, sensitivity 70.1%, and F1 score 67.2%. The ANA patterns with the best performance were centromere (AUC 0.97) and pleomorphic patterns (AUC 0.97).
All 4 developed convolutional neural network (CNN) models performed similarly, with high AUC scores (96.5%–97.1%). These models were meant to differentiate AC-2, which is not associated with SARD, from 2 similar patterns (AC-4 and AC-30), which are associated with SARDs.
There was a strong correlation between titers reported by the identified model and the technologist’s interpretation (Spearman rank 0.93; P<0.0001). In most cases (96.0%), reported titers were identical or differed by only one dilution.
Dr Choi expects the performance of the ANA Reader© to improve further as they continue to train it with more images. The AC-2 model can potentially speed up the differentiation of people who are and are not at risk of SARDs. The group is working on external validation studies and new machine-learning models.
- Choi M, et al. Rheumatology diagnostics utilizing artificial intelligence (ANA Reader©) for ANA pattern identification and titer quantification. Abstract L11, ACR Convergence 2024, 14–19 November, Washington DC, USA.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« ACR presents new 2024 Guideline for lupus nephritis Next Article
Positive results for vagus nerve stimulation in RA »
« ACR presents new 2024 Guideline for lupus nephritis Next Article
Positive results for vagus nerve stimulation in RA »
Table of Contents: ACR 2024
Featured articles
Registry participation can enhance quality of rheumatology care
Meet the Trialist: Prof. Philip J. Mease on the bimekizumab clinical trial program in psoriatic arthritis
Rheumatoid Arthritis
T2T approach in women with RA associated with increased fertility
Positive results for vagus nerve stimulation in RA
Machine learning to aid evaluation of ANA pattern and titer
Systemic Lupus Erythematosus
ACR presents new 2024 Guideline for lupus nephritis
Dapirolizumab pegol associated with less SLE activity and corticosteroid use
Allogeneic CD19-targeting CAR NK-cell therapy for SLE
Osteoarthritis and Osteoporosis
XG005 relieves knee osteoarthritis symptoms in phase 2b study
NT-3 inhibitor relieves pain caused by osteoarthritis
Therapeutic equivalence between denosumab and biosimilar Bmab-1000
Psoriatic Arthritis
Post-hoc analysis of 3 large trials maps sex differences in PsA
Global recruitment associated with higher placebo responses in PsA trials
Gout
Prolonged plasma urate-lowering with a novel pegylated uricase
SGLT2 inhibitor therapy could be beneficial for gout patients
Vasculitis
Fully tapering glucocorticosteroids may be a viable option for GPA
Favourable benefit-risk profile of upadacitinib in giant cell arteritis
Mycophenolate mofetil plus methotrexate is effective in Takayasu’s arteritis
Miscellaneous
Emapalumab rapidly controls MAS in patients with Still’s disease
FcRn blocker nipocalimab improves disease activity in Sjögren’s disease
Inebilizumab associated with reduced flare risk in IgG4-related disease
General Rheumatology
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Related Articles
June 16, 2021
Fenebrutinib at highest dose generally well tolerated
January 14, 2022
Lupus patients less protected by COVID-19 vaccine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com